NIVFW
NewGenIvf Group Limited
NASDAQ · Healthcare · Medical - Care Facilities · VG
$0.02
+25.20%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.9B | 4.7M | 5.4M | 5.1M | 5.9M |
| Cost of Revenue | 1.5B | 3.8M | 3.6M | 3.5M | 4.4M |
| Gross Profit | 465.7M | 955.8K | 1.8M | 1.7M | 1.5M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 4.0B | 11.7M | 3.0M | 1.6M | 1.1M |
| General & Admin Expense | 3.6B | 10.5M | 2.8M | 1.6M | 1.1M |
| Selling & Marketing Expense | 417.1M | 1.2M | 206.3K | 18.0K | 36.2K |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 4.0B | 11.7M | 3.0M | 1.6M | 1.1M |
| Cost and Expenses | 5.5B | 15.5M | 6.6M | 5.1M | 5.5M |
| Operating Income (EBIT) | (3.6B) | (10.7M) | (1.2M) | 42.2K | 398.7K |
| Non-Operating | |||||
| Interest Income | 69.2K | 2.3K | 7.0K | 518.00 | 21.00 |
| Interest Expense | 542.0M | 616.4K | 778.7K | 46.2K | 77.8K |
| Net Interest Income | (542.0M) | (614.2K) | (772.0K) | (45.7K) | (77.7K) |
| Other Non-Op Income/Expense | (4.5B) | 20.5M | 199.7K | 66.2K | (54.7K) |
| Non-Operating Income (excl Interest) | 4.0B | (21.1M) | (978.0K) | (112.0K) | (23.0K) |
| EBT (Pre-Tax Income) | (8.1B) | 9.7M | (961.0K) | 108.4K | 344.0K |
| Income Tax Expense | (487.0K) | — | (487.0K) | — | 208.1K |
| Bottom Line | |||||
| Net Income | (8.0B) | 9.9M | (525.0K) | 130.2K | 458.7K |
| Earnings from Cont. Ops | (8.1B) | 9.7M | (474.0K) | 108.4K | 135.8K |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (8.0B) | 9.9M | (525.0K) | 130.2K | 458.7K |
| Per Share | |||||
| Basic EPS | $368.04 | $604.80 | ($803.03) | $447.67 | $2,250.56 |
| Diluted EPS | $394.68 | $604.80 | ($803.03) | $447.67 | $2,250.56 |
| Revenue Per Share | $6.40 | $289.26 | $332.50 | $705.22 | $816.17 |
| Shares | |||||
| Basic Shares Outstanding | 301.6M | 16340 | 16340 | 7283 | 7283 |
| Diluted Shares Outstanding | — | 16340 | 16340 | 7283 | 7283 |
| Profitability Metrics | |||||
| EBITDA | (7.5B) | 10.8M | 24.3K | 384.3K | 725.7K |
| D&A | 179.9K | 499.5K | 206.3K | 229.7K | 303.9K |
| EBIT | (7.5B) | 10.3M | (182.0K) | 154.6K | 421.7K |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026